378 related articles for article (PubMed ID: 28976221)
1. Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis.
Gaspari T; Spizzo I; Liu H; Hu Y; Simpson RW; Widdop RE; Dear AE
Diab Vasc Dis Res; 2018 Jan; 15(1):64-73. PubMed ID: 28976221
[TBL] [Abstract][Full Text] [Related]
2. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model.
Gaspari T; Liu H; Welungoda I; Hu Y; Widdop RE; Knudsen LB; Simpson RW; Dear AE
Diab Vasc Dis Res; 2011 Apr; 8(2):117-24. PubMed ID: 21562063
[TBL] [Abstract][Full Text] [Related]
3. Ticagrelor, a P2Y12 antagonist, attenuates vascular dysfunction and inhibits atherogenesis in apolipoprotein-E-deficient mice.
Ganbaatar B; Fukuda D; Salim HM; Nishimoto S; Tanaka K; Higashikuni Y; Hirata Y; Yagi S; Soeki T; Sata M
Atherosclerosis; 2018 Aug; 275():124-132. PubMed ID: 29902700
[TBL] [Abstract][Full Text] [Related]
4. Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells.
Uthman L; Homayr A; Juni RP; Spin EL; Kerindongo R; Boomsma M; Hollmann MW; Preckel B; Koolwijk P; van Hinsbergh VWM; Zuurbier CJ; Albrecht M; Weber NC
Cell Physiol Biochem; 2019; 53(5):865-886. PubMed ID: 31724838
[TBL] [Abstract][Full Text] [Related]
5. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice.
Lee DM; Battson ML; Jarrell DK; Hou S; Ecton KE; Weir TL; Gentile CL
Cardiovasc Diabetol; 2018 Apr; 17(1):62. PubMed ID: 29703207
[TBL] [Abstract][Full Text] [Related]
6. RGC-32 (Response Gene to Complement 32) Deficiency Protects Endothelial Cells From Inflammation and Attenuates Atherosclerosis.
Cui XB; Luan JN; Dong K; Chen S; Wang Y; Watford WT; Chen SY
Arterioscler Thromb Vasc Biol; 2018 Apr; 38(4):e36-e47. PubMed ID: 29449334
[TBL] [Abstract][Full Text] [Related]
7. Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-κB activation in human endothelial cells and differentiated macrophages.
Abdollahi E; Keyhanfar F; Delbandi AA; Falak R; Hajimiresmaiel SJ; Shafiei M
Eur J Pharmacol; 2022 Mar; 918():174715. PubMed ID: 35026193
[TBL] [Abstract][Full Text] [Related]
8. Human plasminogen kringle 1-5 reduces atherosclerosis and neointima formation in mice by suppressing the inflammatory signaling pathway.
Chang PC; Wu HL; Lin HC; Wang KC; Shi GY
J Thromb Haemost; 2010 Jan; 8(1):194-201. PubMed ID: 19874473
[TBL] [Abstract][Full Text] [Related]
9. Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium.
Cappetta D; De Angelis A; Ciuffreda LP; Coppini R; Cozzolino A; Miccichè A; Dell'Aversana C; D'Amario D; Cianflone E; Scavone C; Santini L; Palandri C; Naviglio S; Crea F; Rota M; Altucci L; Rossi F; Capuano A; Urbanek K; Berrino L
Pharmacol Res; 2020 Jul; 157():104781. PubMed ID: 32360273
[TBL] [Abstract][Full Text] [Related]
10. Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress.
El-Daly M; Pulakazhi Venu VK; Saifeddine M; Mihara K; Kang S; Fedak PWM; Alston LA; Hirota SA; Ding H; Triggle CR; Hollenberg MD
Vascul Pharmacol; 2018 Oct; 109():56-71. PubMed ID: 29908295
[TBL] [Abstract][Full Text] [Related]
11. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of SGLT2 Rescues Bone Marrow Cell Traffic for Vascular Repair: Role of Glucose Control and Ketogenesis.
Albiero M; Tedesco S; Amendolagine FI; D'Anna M; Migliozzi L; Zuccolotto G; Rosato A; Cappellari R; Avogaro A; Fadini GP
Diabetes; 2021 Aug; 70(8):1767-1779. PubMed ID: 33903150
[TBL] [Abstract][Full Text] [Related]
13. Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice.
Terasaki M; Hiromura M; Mori Y; Kohashi K; Nagashima M; Kushima H; Watanabe T; Hirano T
PLoS One; 2015; 10(11):e0143396. PubMed ID: 26606676
[TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance.
Taberner-Cortés A; Vinué Á; Herrero-Cervera A; Aguilar-Ballester M; Real JT; Burks DJ; Martínez-Hervás S; González-Navarro H
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33287201
[TBL] [Abstract][Full Text] [Related]
15. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
[TBL] [Abstract][Full Text] [Related]
17. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.
Solini A; Giannini L; Seghieri M; Vitolo E; Taddei S; Ghiadoni L; Bruno RM
Cardiovasc Diabetol; 2017 Oct; 16(1):138. PubMed ID: 29061124
[TBL] [Abstract][Full Text] [Related]
18. The anti-inflammatory vasostatin-2 attenuates atherosclerosis in ApoE
Xiong W; Wang X; Dai D; Zhang B; Lu L; Tao R
Thromb Haemost; 2017 Jan; 117(2):401-414. PubMed ID: 27831589
[TBL] [Abstract][Full Text] [Related]
19. Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus.
Kohlmorgen C; Gerfer S; Feldmann K; Twarock S; Hartwig S; Lehr S; Klier M; Krüger I; Helten C; Keul P; Kahl S; Polzin A; Elvers M; Flögel U; Kelm M; Levkau B; Roden M; Fischer JW; Grandoch M
Diabetologia; 2021 Aug; 64(8):1834-1849. PubMed ID: 34131781
[TBL] [Abstract][Full Text] [Related]
20. The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE
Leng W; Ouyang X; Lei X; Wu M; Chen L; Wu Q; Deng W; Liang Z
Mediators Inflamm; 2016; 2016():6305735. PubMed ID: 28104929
[No Abstract] [Full Text] [Related]
[Next] [New Search]
